Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.

Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.

Cancer Cell. 2006 Jun;9(6):485-95. Epub 2006 May 25.

2.
3.

Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?

Inamura K, Ninomiya H, Ishikawa Y, Matsubara O.

Arch Pathol Lab Med. 2010 Jan;134(1):66-72. doi: 10.1043/2008-0586-RAR1.1. Review.

PMID:
20073607
4.

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF.

Clin Cancer Res. 2004 Dec 15;10(24):8195-203.

5.

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

6.

Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.

Taja-Chayeb L, Candelaria M, Brom R, Trejo-Becerril C, Meza F, Duenas-Gonzalez A.

Lung Cancer. 2005 Nov;50(2):259-63. Epub 2005 Jul 11.

PMID:
16009451
7.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2006 Nov 1;12(21):6494-501.

8.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

9.

Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.

Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V.

Diagn Cytopathol. 2007 May;35(5):257-62.

PMID:
17427221
10.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

PMID:
22000696
11.

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.

Irmer D, Funk JO, Blaukat A.

Oncogene. 2007 Aug 23;26(39):5693-701. Epub 2007 Mar 12. Review.

PMID:
17353898
12.

Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.

Ohashi K, Takigawa N, Osawa M, Ichihara E, Takeda H, Kubo T, Hirano S, Yoshino T, Takata M, Tanimoto M, Kiura K.

Cancer Res. 2009 Sep 1;69(17):7088-95. doi: 10.1158/0008-5472.CAN-08-4205. Epub 2009 Aug 18.

13.

Predictors of the response to gefitinib in refractory non-small cell lung cancer.

Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, Baek SM, Park CS, Park CM, Kim YI, Lim SC, Park KO.

Clin Cancer Res. 2005 Mar 15;11(6):2244-51.

14.

K-ras mutations in lung cancer: the "mysterious mutation".

Hirsch FR.

Clin Lung Cancer. 2006 Jul;8(1):11-2. No abstract available.

PMID:
16870039
15.

Targeting targeted therapy.

Green MR.

N Engl J Med. 2004 May 20;350(21):2191-3. Epub 2004 Apr 29. No abstract available.

16.

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.

Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22. Epub 2006 May 3.

17.

HKI-272 in non small cell lung cancer.

Wong KK.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4593-6. Review.

18.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
19.

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.

Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.

PMID:
22082647
20.

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM.

Cancer Res. 2005 Dec 15;65(24):11478-85.

Supplemental Content

Support Center